Contents
Special Issue Topic

Nanomedicine and Cancer Immunotherapy

Guest Editors

Dr. Haijun Yu E-Mail

Principal Investigator, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

Research Keywords: Nanomedicine, immunotherapy, drug delivery, gene therapy, biomedical engineering

Dr. Yang Shi E-Mail

Group Leader, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Helmholtz Institute for Biomedical Engineering, Aachen, Germany

Research Keywords: Nanomedicine, immunotherapy, tumor targeting, biomaterials, biomedical engineering

About the Special lssue

Immunotherapy has shifted the paradigm of cancer research and management both in laboratory and clinic. Cancer immunotherapy with immune checkpoint inhibitors or small molecular agonists has been employed to initiate systemic and sustainable antitumor immune response for tumor regression and metastasis suppression. However, the therapeutic benefits for cancer immunotherapy are impaired by the moderate response rate and severe immune-related reverse effects. The advances of caner nanomedicine show promising potential for improving cancer immunotherapy by optimizing the pharmacokinetic profiles of immune modulators and co-delivery of multiple therapeutic agents.

In this special issue of “Nanomedicine and Cancer Immunotherapy”, we welcome both review articles and original research papers to summarize the most recent advances of nanomedicine for cancer vaccination, improved delivery of tumor antigen, delivery of small molecular immune modulators, etc. This special issue should be of high impact improving the understanding and clinical translation of nano-immunotherapy.

Keywords: Nanomedicine, cancer immunotherapy, tumor immune microenvironment, drug delivery, adaptive immune response, innate immune response

Published Articles

Open Access Review
Nano-immunotherapeutics: targeting approach as strategic regulation at tumor microenvironment for cancer treatment
Cancer is the leading cause of mortality worldwide, which necessitates our consideration related to novel treatment approach. Tumor cells at the tumor microenvironment (TME), regulate a plethora of
Published: February 16, 2022 Explor Med. 2022;3:22–42
2836 55 1
Open Access Review
Emerging nanomaterials for cancer immunotherapy
Immunotherapy is a unique approach to treat cancer that targets tumours besides triggering the immune cells. It attempts to harness the supremacy and specificity of immune cells for the regression of malignancy. The key strategy of immunotherapy is that it boosts the natural defence and manipulates the immune system at both cellular and molecular levels.
Published: June 30, 2021 Explor Med. 2021;2:208–231
3445 75 2
Open Access Review
AS1411-functionalized delivery nanosystems for targeted cancer therapy
Nucleolin (NCL) is a multifunctional nucleolar phosphoprotein harboring critical roles in cells such as cell proliferation, survival, and growth. The dysregulation and overexpression of NCL are related to various pathologic and oncological indications. These characteristics of NCL make it an ideal target for the treatment of various cancers. AS1411 is a synthetic quadruplex-forming nuclease-resistant DNA oligonucleotide aptamer which shows a considerably high affinity for NCL, therefore, being capable of inducing growth inhibition in a variety of tumor cells.
Published: April 30, 2021 Explor Med. 2021;2:146–166
4627 85 3
Open Access Review
Nanomedicine in cancer therapy: promises and hurdles of polymeric nanoparticles
The limitations of current cancer treatments have stimulated the application of nanotechnology to develop more effective and safer cancer therapies. Remarkable progress has been made in the development of nanomedicine to overcome issues associated with conventional cancer treatment, including low drug solubility, insufficient targeting, and drug resistance.
Published: April 30, 2021 Explor Med. 2021;2:167–185
4392 83 4
Open Access Review
Cell-derived vesicles for delivery of cancer immunotherapy
In recent years, cancer immunotherapy has received unprecedented attention due to the clinical achievements. The applications of biomedical engineering and materials science to cancer immunotherapy have solved the challenges caused by immunotherapy to a certain extent. Among them, cell-derived vesicles are natural biomaterials chosen as carriers or immune-engineering in view of their many unique advantages. This review will briefly introduce the recent applications of cell-derived vesicles for cancer immunotherapy.
Published: February 28, 2021 Explor Med. 2021;2:39–59
4255 77 1